DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each approved by major agencies including FDA, EMA, HMA, CFDA, and PMDA, or listed in authoritative pharmacopeias [APExBIO]. Compounds are provided as 10 mM DMSO solutions, validated for stability (12 months at -20°C, 24 months at -80°C). The library enables high-throughput and high-content screening (HTS/HCS), supporting drug repositioning and mechanism-of-action studies across oncology, neurodegeneration, and other disease models [Yin et al., 2022]. Mechanistic coverage spans receptor modulation, enzyme inhibition, ion channel targeting, and signal pathway regulation. The kit is engineered for workflow compatibility, with formats including 96-well plates and 2D barcoded tubes.

Biological Rationale

Drug discovery increasingly relies on bioactive compound libraries to interrogate complex cellular processes and identify new therapeutic opportunities. The DiscoveryProbe™ FDA-approved Drug Library from APExBIO aggregates 2,320 compounds with established clinical safety profiles, maximizing translational relevance. These compounds span diverse mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators [see also]. This approach enables rapid, hypothesis-driven screening for drug repositioning and facilitates pharmacological target discovery, as demonstrated in recent high-throughput screens (Yin et al., 2022, DOI). By leveraging only clinically approved agents, the library reduces translational risk and expedites preclinical validation cycles.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe library features compounds with well-annotated mechanisms of action (MOA). These include:

• Receptor agonists and antagonists targeting GPCRs, nuclear receptors, and ion channels.
• Enzyme inhibitors, such as kinase, proteasome, and phosphodiesterase inhibitors.
• Ion channel modulators for potassium, sodium, and calcium channels.
• Signal pathway regulators, including compounds modulating cAMP/PKA, MAPK/JNK, and redox-sensitive cascades.

For example, doxorubicin (an anthracycline DNA intercalator), metformin (an AMPK activator), and atorvastatin (an HMG-CoA reductase inhibitor) are represented, illustrating the library’s mechanistic breadth. Proteasome inhibitors within the collection have been shown to activate CREB signaling via ROS/JNK pathways in high-throughput Drosophila screens (Yin et al., 2022). This diversity supports interrogation of cellular stress responses, signal transduction, and disease-associated protein aggregation.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library enables rapid identification of CREB-activating compounds, including all proteasome inhibitors tested in a validated Drosophila model (Yin et al., 2022, DOI).
• Compounds in the L1021 kit are pre-dissolved at 10 mM in DMSO and retain ≥95% purity and activity for up to 24 months at -80°C (APExBIO product data, product page).
• High-throughput screening of this library has identified new modulators of redox-sensitive signaling and protein homeostasis in neurodegenerative disease models (Yin et al., 2022, DOI).
• Screening outcomes are reproducible across both cell-based and whole-organism assays, supporting its application in diverse workflow settings (internal benchmark).
• Compared to custom compound sets, regulatory-vetted collections like DiscoveryProbe accelerate the translation of screening hits to clinical hypotheses (internal analysis).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a range of translational and basic research applications, including:

• Cancer research drug screening for cytotoxicity, cell signaling, and resistance mechanisms.
• Neurodegenerative disease drug discovery, especially for protein aggregation and proteostasis modulation.
• Drug repositioning screening to identify new indications for existing agents.
• Enzyme inhibitor screening and mapping of signal pathway regulation.
• High-content screening in disease models for phenotypic profiling.

For a scenario-driven perspective on addressing experimental pain points, see this article, which this page extends by providing updated mechanistic insights from recent peer-reviewed screens.

Common Pitfalls or Misconceptions

• Not all compounds are equally soluble at 10 mM in DMSO: Some compounds may precipitate upon freeze-thaw cycles or prolonged storage above -20°C.
• HTS assay conditions must be validated for DMSO tolerance: Final DMSO concentrations >0.5% may induce off-target effects in some cell lines.
• Library is designed for in vitro and ex vivo screens: Direct in vivo administration requires pharmacokinetic and toxicity validation.
• Mechanism annotation is based on best-available clinical and preclinical data: Off-target effects or polypharmacology may complicate hit interpretation.
• Regulatory approval does not guarantee efficacy for new indications: Repositioning hits require full preclinical and clinical validation.

Workflow Integration & Parameters

DiscoveryProbe™ FDA-approved Drug Library is supplied in ready-to-screen 10 mM DMSO solutions, compatible with 96-well microplates, deep-well plates, and 2D barcoded storage tubes. For optimal performance:

• Store at -20°C for up to 12 months; for extended storage (up to 24 months), use -80°C.
• Thaw only required aliquots; avoid repeated freeze-thaw cycles.
• Assay setup: typical final screening concentration is 1–10 μM per compound, with DMSO kept ≤0.5% v/v in assay wells.
• Shipping is on blue ice for evaluation samples; room temperature or blue ice available for larger batches.
• Data quality improves with controls for DMSO, known actives, and signal pathway markers.

For workflow integration guidance, this resource offers practical recommendations extending the mechanistic analysis presented here, especially for advanced translational teams.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library by APExBIO delivers a comprehensive, mechanistically diverse collection for high-throughput and high-content drug discovery workflows. By uniting regulatory approval with robust stability and workflow flexibility, the L1021 kit accelerates pharmacological target identification and supports modern drug repositioning strategies. Ongoing integration of peer-reviewed screening data and translational best practices will continue to enhance its value for oncology, neurodegeneration, and beyond.